while percentage ID/g of F(ab')2 was 2.4 and T/B was 3.2. Percentage ID/g decreased after day I while T/B increased. In these experiments no preferential localisation of either isotype matched '251I-labelled control IgG or F(ab')2 was observed. In F(ab')2 injected HNX-HN bearing mice as well as VX-A431 bearing mice, tumours could be visualised at day 1 and 2 without any appreciable background activity. With MAb IgG this was also possible in HNX-HN bearing mice (but not in VX-A431 bearing mice) but only at day 3 and 6. These findings suggest that the superior tumour to non-tumour ratios render the E48 F(ab')2 fragment more qualified for specific targeting of radioisotopes to tumour xenografts in this experimental setting.
Of all human neoplasms, squamous cell carcinoma (SCC) is one of the most common tumour types and represents the major histological type of neoplasm arising from head and neck, cervix, skin, and lung. The relative sensitivity of head and neck SCC for radiation therapy has led us to investigate the possibility of using monoclonal antibodies (MAb's) directed against tumour associated antigens (TAA's) to specifically target radioisotopes to SCC tumours.
So far, only a limited number of MAb's to SCC have been described (Carey et al., 1983; Zenner & Herman, 1981; Boeheim et al., 1985; Kimmel & Carey, 1986; Fernsten et al., 1986; Koprowska et al., 1986; Brenner et al., 1982; Kyoizumi et al., 1985; Myoken et al., 1987; Ranken et al., 1987; Samuel et al., 1989; Tatake et al., 1989) . Most of these antibodies show considerable cross reactivity with normal tissues or only show reactivity with SCC of distinct sites of origin. Among the few MAb's reacting with SCC originating from various organs are MAB 17.13 (Ranken et al., 1987) , an IgM isotype antibody and thus less suited for in vivo immunolocalisation studies; MAb 174H.64 (Samuel et al., 1989) , reacting with a cytoskeletal protein, which possibly contains extracellular domains, and MAb 3F8E3 (Tatake et al., 1989) which is a low affinity antibody.
We have developed a MAb designated E48, raised against a SCC of the larynx, which shows strong and selective reactivity to squamous epithelia and their neoplastic derivatives of various tissue sites (Quak et al., 1990a ). Recently, we described the capacity of MAb E48 IgG for highly specific delivery of radioisotopes in nude mice carrying human head and neck SCC xenografts (Quak et al., 1989) . However, F(ab')2 fragments have been demonstrated to have better tumour to non-tumour ratios in nude mice bearing xenografts due to a more rapid clearance from the blood (Pervez et al., 1988; Colapinto et al., 1988; Buchegger et al., 1986; Endo et al., 1988) . These superior tumour to non-tumour ratios resulted in much lower background levels and improved tumour images.
In this investigation, we have compared the characteristics of E48 IgG and E48 F(ab')2 fragment with regard to biodistribution and imaging in nude mice bearing SCC xenografts. Two xenograft lines, the head and neck SCC xenograft line HNX-HN and the vulva SCC xenograft line VX-A431, were selected from a panel of xenograft lines based on the E48 antigen expression. These tumours represent the heterogeneity of the E48 immunohistochemical reaction pattern as observed in 92 human tumours and eight SCC xenograft lines available at our laboratory. Immunohistochemical examination of E48 expression in the HNX-HN line revealed strong homogenous membrane bound expression and to a lesser extent cytoplasmatic expression while the E48 expression pattern in the VX-A431 line was shown to be moderate and diffuse.
Materials and methods
MAb IgG and F(ab')2 fragments MAb E48 (IgGI) detects a 22 kDa surface antigen which, in normal tissues, is exclusively expressed in stratified squamous epithelia and transitional epithelia (Quak, 1990a) . So far tested, MAb E48 reacted with 91 out of 93 SCC of head and neck, lung, cervix and skin, while out of 42 non-SCC tumours, 40 showed no binding. The isotype-matched control antibody JSB-1, directed against the P-glycoprotein related to multidrug resistance and not reactive with the xenograft in our study, has been described in detail elsewhere (Scheper et al., 1988 Haisma et al. (1986) . 500g of IgG or F(ab')2 fragment was mixed with 1 mCi 1251 or 1311 and specific activity of the conjugate was determined. After removing excess unbound iodine, percentage of incorporated radioactivity was determined.
MAb IgG and F(ab')2 in vitro binding assays The binding characteristics of radiolabelled MAb E48 and E48 F(ab')2 were analysed by immunoreactivity and affinity assays. The immunoreactivity assay was performed essentially as described by Lindmo et al. (1984) . In short, A431 cells were fixed in 0.1% glutaraldehyde and six serial dilutions, ranging from 5 x 106 cells per tube to 3.1 x 105 cells per tube, were made with 1% bovine serum albumin (BSA) in PBS. 10,000 cpm of the labelled MAb or F(ab')2 fragment were added to the tubes and incubated overnight at room temperature. Excess unlabelled MAb or F(ab')2 fragment was added to the last sample to determine non-specific binding. Cells were spun down and radioactivity in the pellet and supernatant was determined in a gamma counter and the percentage bound and free radiolabelled MAb Pharmacokinetics of MAb and F(ab')2 fragments At day 1, 2, 3 and 6 (HNX-HN) or 1, 2, 3 and 7 (VX-A431), serum samples were collected to determine free iodine. Less than 5% free iodine was present as revealed by TCA precipitation. At day 1 after injecting the labelled MAb IgG and F(ab')2 9.32 to 11.66% ID/g E48 IgG and 12.11 to 12.21% ID/g JSB-1 IgG was present in the blood, whereas 0.53 to 0.74% ID/g E48 F(ab')2 fragment and 0.83 to 1.30% ID/g JSB-l F(ab')2 was present in the blood, indicating a much faster clearance of F(ab')2 fragments from the blood as compared to whole IgG. (Figure 4a ). To exclude the possibility that uptake might be due to non-specific protein trapping, an isoptye matched antibody and its F(ab')2 fragment were included as a control. The control IgG and control F(ab')2 did not show any specific accumulation, either in the tumours or in any organ (Figures 3b and 4b) . Table Ila and Ilb show the specific localisation index (SLI) of E48 IgG and E48 F(ab')2 fragments, calculated by dividing the percentage ID/g of specific IgG or F(ab')2 fragment (E48) in the tumour by the percentage ID/g of control IgG or F(ab')2 fragment (JSB-1). In the course of the experiment, SLI of E48 IgG did not change significantly (3.7 at day 1 to 5.8 at day 6), whereas SLI of E48 F(ab')2 fragment reached a maximum of 28.4 at day 6.
Tumour uptake of E48 IgG and E48 F(ab')2 fragment in VX-A431 bearing mice The percentage ID/g of 13'I E48 IgG and 13'I E48 F(ab')2 fragment in xenografts and various organs was determined as above. Tables Illa and ITlb Figure Sa) . Table IVa and IVb show the SLI of E48 IgG and E48 F(ab')2 fragment. E48 IgG did not show a pronounced specific localisation in the tumour xenografts, as reflected by the low SLI of E48 IgG (Table IVa) . E48 F(ab')2 however did show appreciable specific localisation (Table  IVb) , with SLI being 4.1 at its maximum at day 1. The control IgG (data not shown) and control F(ab')2 (Figure 5b ) did not show any specific accumulation in the tumours nor in any organ.
Uptake in other organs The percentage of E48 IgG and E48 F(ab')2 fragment in various organs of HNX-HN bearing mice is presented in Figure 3a and Figure 4a . Only the most relevant organs are shown, the uptake in heart, stomach, jejenum, muscle, lung and tongue being comparable to or lower than uptake in colon. Sternum is shown because of the presence of haemopoietic tissue. The percentage ID/g of IgG (data not shown) and E48 F(ab')2 (Figure 5a) (Figure 6a ) as well as day 2 (Figure 6b ). This background activity only markedly decreased 2 days after injection, after which timepoint xenografts could be visualised without appreciable background disturbance (Figure 6c, Figure 6d ). given an injection of 10liCi "lI E48 IgG. Images were taken at day I a, day 2 b, day 3 c and day 6 d. Weight of xenografts in mg from left to right: a: 577, 575, 463, 464; b: 772, 211, 148, 341; c: 297, 472, 255, 694; d: 252, 379, NX, 766 (NX = no xenograft present).
Figures 7a and b represent mice being scanned 1 day and 2 days after injection of 10 Ci '3'I-labelled E48 F(ab')2 fragment per mouse. Percentage ID/g at day 1 was of 6.09, 6.12, 8.28 and 9.03 from left to right, respectively (Figure 7a ), and at day 2 percentage ID/g was 4.28, 6.11 and 3.24 and 2.89 from left to right, respectively (Figure 7b) . No background activity could be detected, resulting in images showing only xenograft localisation of radioisotope.
VX-A431 mice Images of mice injected with 10sCi 31TI-labelled E48 IgG did not result in identification of xenografts at any timepoint after injection, due to consistent high blood pool activity (images not shown). Images of mice injected with 10 lCi '31I-labelled E48 F(ab')2 however, 1 day ( Figure  8a ) and 2 days (Figure 8b) (Smith et al., 1979) . Finally, the smaller size of fragments should allow better tumour penetration than whole IgG. Although these phenomena hold true for both Fab and F(ab')2, reports dealing with studies on tumour uptake of whole IgG, F(ab')2
and Fab often show a strong decrease in tumour uptake of F(ab')2 and Fab when compared to whole IgG and a strong decrease in tumour to normal tissue ratios of Fab when compared to F(ab')2, most likely the result of increased clearance from the blood and a decreased affinity inherent in the generation of univalent Fab fragments (Buchegger et al., 1986; Colapinto et al., 1988; Endo et al., 1988; Wahl et al., 1983) .
In this investigation we compared the characteristics of E48 IgG and E48 F(ab')2 with regard to biodistribution and imaging parameters in nude mice bearing SCC xenografts. In a previous study we reported the production of MAb E48 recognising a 22 kDa antigen exclusively expressed in stratified squamous epithelia and transitional epithelium of the bladder (Quak et al., 1990a,b (Quak et al., 1989) . In nude mice bearing the HNX-HN xenograft line, the use of the F(ab')2 fragment of E48 strongly improved tumour uptake ratios and localisation specificity when compared directly with IgG. Although the digestion of IgG for the generation of F(ab')2 did not significantly alter the affinity of the radiolabelled conjugate, F(ab')2 did show a decrease in percentage ID/g tumour tissue as compared to IgG. Differences in pharmacokinetics of the conjugates are likely to be the major factors leading to this decrease. However, the improved tumour uptake ratios and specificity of localisation resulted in images without background disturbance at day 1 for F(ab')2, whereas IgG did not give comparable images until day 3. In nude mice bearing the xenograft line VX-A431, E48 IgG uptake in tumours did not differ from control IgG, thus failing to reach tumour to non tumour ratios enabling visualisation of tumour xenografts at any time point. E48 F(ab')2 fragments however did show specific localisation in tumour tissue, and although the percentage ID/g was almost one third of the percentage ID/g of E48 F(ab')2 in HNX-HN bearing mice and the SLI of F(ab')2 in VX-A431 bearing mice was less than half the SLI of F(ab')2 in HNX-HN bearing mice, tumours could still well be visualised at day 1. These differences in percentage ID/g and specificity of localisation between the HNX-HN and VX-A431 xenograft lines might be due to such variables as vascularisation, blood vessel morphology and permeability, tumour microcirculation, necrosis, composition of extracellular matrix and intratumoural hydrostatic pressure, parameters likely to be of considerable influence on the efficacy of non-surgical modalities (Sands et al., 1988; Cobb, 1989; Kallinowski et al., 1989; Jain & Wie, 1977; Sweet et al., 1979; Hori et al., 1986) .
Additionally, differences in number and exposition of antigenic sites cannot be ruled out as major factors in causing the differences in localisation of the radiolabelled conjugates between the two xenograft lines. A lower number of exposed antigenic sites per cell in the VX-A431 xenograft line as compared to the HNX-HN xenograft line combined with the higher penetration capacities of the small E48 F(ab')2 fragment as compared to E48 IgG might very well explain the inability of E48 IgG to localise specifically in the VX-A431 xenograft line. In this perspective, the differences in localisation characteristics between the HNX-HN and the VX-A431 xenograft lines might reflect the heterogeneity of expression and accessibility of antigenic sites in human tumours in the clinical situation.
In normal tissues, neither E48 IgG nor E48 F(ab')2 showed any non specfic accumulation in vital organs, including the radiation sensitive reticuloendothelial system (liver, spleen and bone marrow). The overall tumour to non-tumour ratios of F(ab')2 however were several times higher than tumour to non tumour ratios of IgG. Tumour to non-tumour ratios of F(ab')2 in VX-A431 bearing mice were still higher than tumour to non-tumour ratios of IgG in HNX-HN bearing mice.
So far, only a limited number of MAb's reacting with human squamous cell carcinoma have been described. Most of these antibodies show considerable cross reactivity with other tissues or only show reactivity with SCC of distinct sites of tissue origin. Additionally, features of these antibodies as isotype, cytoplasmatic localisation of the antigen and relatively low affinity of the antibody render them less suited for in vivo localisation studies or application in a clinical setting.
Within the limitations of our experiments, we have shown the E48 F(ab')2 fragment to be a promising candidate for immunodiagnostic application in a clinical setting. Preparations for a phase I/II clinical study are currently in progress.
